Medicare AdvantageCoverageMedium impact
Medicare: Vyndaqel will be discontinued on Dec. 31
UnitedHealthcare·Cardiology·Medicare plan updates
Effective date
Dec 31, 2025
We identified it
Jan 12, 2026
Summary
Pfizer is discontinuing Vyndaqel (tafamidis meglumine) effective December 31, 2025 for treating transthyretin amyloid cardiomyopathy. UnitedHealthcare Medicare Advantage and Part D plans will cover Vyndamax (tafamidis) as the alternative, and existing Vyndaqel prior authorizations can transition to Vyndamax without requiring new authorization.
Action Required
By December 31, 2025: Billing team must coordinate with providers to ensure patients on Vyndaqel receive new prescriptions for Vyndamax before the discontinuation date. Update medication lists and prior authorization records to reflect the transition from Vyndaqel to Vyndamax. No new prior authorization required for existing Vyndaqel patients switching to Vyndamax.